INT187778

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.33
First Reported 2005
Last Reported 2010
Negated 1
Speculated 0
Reported most in Body
Documents 12
Total Number 12
Disease Relevance 7.37
Pain Relevance 0.35

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (Slc11a1) molecular_function (Slc11a1) cellular_component (Slc11a1)
biological_process (Slc11a1) lysosome (Slc11a1)
Anatomy Link Frequency
upper 1
Slc11a1 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
abdominal pain 7 96.16 Very High Very High Very High
Arthritis 5 79.92 Quite High
Inflammation 5 55.84 Quite High
Neuritis 5 38.88 Quite Low
Pain 3 20.64 Low Low
anesthesia 3 5.00 Very Low Very Low Very Low
cva 3 5.00 Very Low Very Low Very Low
imagery 3 5.00 Very Low Very Low Very Low
corticosteroid 2 5.00 Very Low Very Low Very Low
aspirin 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Carcinoma In Situ 68 99.96 Very High Very High Very High
Recurrence 117 99.92 Very High Very High Very High
Erythema 6 98.54 Very High Very High Very High
Transitional Cell Carcinoma 26 98.04 Very High Very High Very High
Diarrhoea 4 96.68 Very High Very High Very High
Infection 52 96.60 Very High Very High Very High
Abdominal Pain 7 96.16 Very High Very High Very High
Cicatrix 28 94.68 High High
Sepsis 7 94.04 High High
Bladder Cancer 66 93.60 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
With regard to the population of the EORTC trial, BCG therapy was carried out in only 5.9% of the population and intravesical chemotherapy (thiotepa, epirubicin, mitomycin C, or pyridoxine) was carried out in the remaining patients.
Gene_expression (therapy) of BCG
1) Confidence 0.33 Published 2010 Journal Korean Journal of Urology Section Body Doc Link PMC2855454 Disease Relevance 1.29 Pain Relevance 0
The BCG used by the authors was Oncotice┬«, which contained Tice BCG 2-8├Ś108 CFU/ml.
Gene_expression (contained) of BCG
2) Confidence 0.33 Published 2010 Journal Korean Journal of Urology Section Body Doc Link PMC2855454 Disease Relevance 1.39 Pain Relevance 0
78% (39 out of 50) of children in Group I (prior BCG vaccination given) and 18% (9 out of 50) in Group II (prior BCG vaccination not given) had exaggerated BCG response; defined as induration greater than or equal to 6 mm.
Gene_expression (vaccination) of BCG
3) Confidence 0.25 Published 2005 Journal BMC Infect Dis Section Body Doc Link PMC1274275 Disease Relevance 0.28 Pain Relevance 0
Out of 50 children in Group I (children who were given prior BCG vaccination), 39 (i.e. 78 per cent) had exaggerated BCG Test responses while in Group II (children who were not given prior BCG vaccine) only 9 (18 per cent) out of 50 cases had exaggerated BCG Test response (Refer to Table 1).
Gene_expression (vaccination) of BCG
4) Confidence 0.25 Published 2005 Journal BMC Infect Dis Section Body Doc Link PMC1274275 Disease Relevance 0.13 Pain Relevance 0
Significant number (78%) of normal children with previous BCG vaccination, who were Mantoux negative and received BCG as a 'diagnostic test' or as revaccination, showed, exaggerated BCG response.
Gene_expression (vaccination) of BCG
5) Confidence 0.25 Published 2005 Journal BMC Infect Dis Section Body Doc Link PMC1274275 Disease Relevance 0.26 Pain Relevance 0
78% (39 out of 50) of children in Group I (prior BCG vaccination given) and 18% (9 out of 50) in Group II (prior BCG vaccination not given) had exaggerated BCG response; defined as induration greater than or equal to 6 mm.
Gene_expression (response) of BCG
6) Confidence 0.25 Published 2005 Journal BMC Infect Dis Section Body Doc Link PMC1274275 Disease Relevance 0.27 Pain Relevance 0
Out of 50 children in Group I (children who were given prior BCG vaccination), 39 (i.e. 78 per cent) had exaggerated BCG Test responses while in Group II (children who were not given prior BCG vaccine) only 9 (18 per cent) out of 50 cases had exaggerated BCG Test response (Refer to Table 1).
Gene_expression (vaccine) of BCG
7) Confidence 0.25 Published 2005 Journal BMC Infect Dis Section Body Doc Link PMC1274275 Disease Relevance 0.18 Pain Relevance 0
A recently published large series of treating 133 renal units over a 20-year period demonstrated no benefit in reducing recurrence or progression with adjuvant BCG following percutaneous resection of upper tract TCC.[30] If adjuvant BCG is given, it is recommended that to avoid systemic absorption and possible sepsis, instillation of agents to the upper tract should be performed under low pressure (25 cm water) and in the absence of infection.[16] Close observation after BCG is recommended for 24 hours; with immediate cessation of therapy and prompt initiation of anti-tuberculous treatment if systemic symptoms develop.[31]

RESULTS

Gene_expression (progression) of BCG in upper associated with infection, sepsis, transitional cell carcinoma and recurrence
8) Confidence 0.04 Published 2010 Journal Indian Journal of Urology : IJU : Journal of the Urological Society of India Section Body Doc Link PMC2938538 Disease Relevance 0.64 Pain Relevance 0
Erythema and induration at the site of BCG vaccination is common in Japan, where BCG is used widely.25 As in Japan, BCG is routinely performed in Turkey, but only one patient had redness and induration at the site of the BCG scar.
Gene_expression (used) of BCG associated with cicatrix and erythema
9) Confidence 0.03 Published 2010 Journal Clinics (Sao Paulo) Section Body Doc Link PMC3020335 Disease Relevance 1.81 Pain Relevance 0.33
Bropirimine, an oral immunomodulator, was studied in BCG-resistant CIS in a phase-II trial [23].
Gene_expression (resistant) of BCG associated with carcinoma in situ
10) Confidence 0.02 Published 2009 Journal World J Urol Section Body Doc Link PMC2694311 Disease Relevance 0.75 Pain Relevance 0
Of 67 PCR negative cases, anti-MPT64 and anti-BCG were negative in 65 and 57 respectively, thus giving a specificity of 93% for anti-MPT64 and 88% for anti-BCG (table 4).
Neg (negative) Gene_expression (negative) of BCG
11) Confidence 0.01 Published 2007 Journal Diagn Pathol Section Body Doc Link PMC2203973 Disease Relevance 0.18 Pain Relevance 0
All ZN and culture positive cases were positive for anti-MPT64, anti-BCG and PCR while ZN was positive in only 14 culture positive cases.
Gene_expression (positive) of BCG
12) Confidence 0.00 Published 2007 Journal Diagn Pathol Section Body Doc Link PMC2203973 Disease Relevance 0.19 Pain Relevance 0.03

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox